Comorbid Metabolic Syndrome, Psoriatic Arthritis Linked to Reduced Health-Related Quality of Life
Patients with plaque psoriasis have a reduced health-related quality of life, mainly in terms of emotional aspects.
Hypertension
HYPERTENSION
Latest News
Cardiovascular Comorbidity Screening Should Be Conducted in COPD With Obesity
Hypertension and diabetes are especially prevalent comorbidities in obese patients with chronic obstructive pulmonary disease.
Primary Hypertension May Not Affect Prognosis of Postmenopausal Osteoporosis
The presence of primary hypertension does not appear to have an effect on the prognosis of postmenopausal osteoporosis.
Reducing Systolic Blood Pressure With Liraglutide: Predictors and Correlates
Patients with type 2 diabetes treated with liraglutide experience a greater reduction in systolic BP if they have lower baseline continuous glucose monitoring values and higher diastolic BP.
Edentulism Associated With Risk for Hypertension After Menopause
Postmenopausal women with edentulism are at an increased risk for developing hypertension.
Interpregnancy Period Should Maximize Women’s Health
Providers should maximize women’s health during the interpregnancy period, continuing care beyond the immediate postpartum period.
Knit One, Purl One: The Health Benefits of Knitting
Knitting is both process- and product-oriented, encompassing repetitive tasks that can exercise physical and cognitive skills
Metabolic Syndrome Highly Prevalent in Patients With Plaque Psoriasis
Metabolic syndrome and psoriatic arthritis were highly prevalent comorbidities in patients with plaque psoriasis.
Hypertensive Disorders in Pregnancy, Postpartum BMI Linked to T2D Risk
Postpartum women with an elevated BMI score and a history of hypertensive disorders during pregnancy have an increased risk of developing type 2 diabetes.
Digital Obesity Treatment in Primary Care May Help Disadvantaged Patients
Socioeconomically challenged patients with obesity and elevated cardiovascular risk may benefit from digital obesity treatment combined with health system resources.
Another Antihypertensive Recalled Due to Potentially Carcinogenic Impurity
The impurity was identified following laboratory testing conducted by the Food and Drug Administration (FDA); this is the first non-valsartan product that the Agency has found to contain NDEA.
Want to read more?
Please login or register first to view this content.
